Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population

Journal of Thrombosis and Thrombolysis

Volumn 32, Issue 3, 2011, Pages 328-333

  Alexopoulos, Dimitrios ^a   Xanthopoulou, Ioanna ^a   Mylona, Panagiota ^a   Perperis, Angelos ^a   Panagiotou, Aggeliki ^a   Dimitropoulos, Gerasimos ^a   Tsigkas, Grigorios ^a   Hahalis, George ^a   Davlouros, Periklis ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Acute coronary syndromes; Antiplatelet treatment; Percutaneous coronary intervention; Prasugrel

Indexed keywords

PRASUGREL;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG USE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; AGED, 80 AND OVER; DIABETES MELLITUS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PIPERAZINES; PREVALENCE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; STROKE; THIOPHENES;

EID: 82955203400     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0610-9     Document Type: Article

References (15)

1. Brandt JT, Payne CD, Wiviott SD et al (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153:66.e9-66.e16
2. Jakubowski JA, Matsushima N, Asai F et al (2007) A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 63:421-430 (Pubitemid 46426638)
3. Wallentin L, Varenhorst C, James S et al (2008) Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29:21-30
4. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015 (Pubitemid 350106708)
5. Prasugrel prescribing information. Center for drug evaluation and research. www.accessdata.fda.gov/drugsatfda-docs/label/2009/022307s000lbl.pdf. Access date 23/12/2010
6. Kushner FG, Hand M, Smith SC Jr et al (2009) American College of Cardiology Foundation/American Heart Association task force on practice guidelines 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update). A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines circulation, vol 120, pp 2271-2306
7. Bhatt DL (2009) Prasugrel in clinical practice. N Engl J Med 361:940-942
8. Antman EM, Cohen M, Bernink PJ et al (2000) The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284: 876-878
9. Alexander KP, Chen AY, Roe MT et al (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294: 3108-3116 (Pubitemid 43016802)
10. Mahaffey KW, Harrington RA, Simoons ML et al (1999) Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 99:2371-2377 (Pubitemid 29218230)
11. Wiviott SD, Braunwald E, Angiolillo DJ et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction. Circulation 118:1626-1636
12. Wrishko RE, Ernest CS II, Small DS et al (2009) Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol 49:984-998
13. Serebruany VL, Albert MJs, Hanley DF (2008) Prasugrel in the poststroke cohort of the TRITON trial. Clear Present Danger Cerebrovasc Dis 26:93-94
14. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057
15. Steg PG, James S, Harrington RA et al (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 122:2131-2141